[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.104.49. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1970

The Effect of Glucagon on Hepatic Blood FlowAn Experimental Study in the Dog

Author Affiliations

Buffalo
From the Department of Surgery, State University of New York at Buffalo, and the Surgical Research Laboratories of the Edward J. Meyer Memorial Hospital, Buffalo. Dr. Kock is now at the University of Göteborg, Göteborg, Sweden; Dr. Roding, the University of Amsterdam, Amsterdam; Dr. Hahnloser, the University Surgical Clinic, Zurich, Switzerland; and Dr. Tibblin, the University of Lund, Lund, Sweden. Drs. Kock, Roding, Hahnloser, and Tibblin participated in this study as Buswell fellows in surgical research.

Arch Surg. 1970;100(2):147-149. doi:10.1001/archsurg.1970.01340200035008
Abstract

Glucagon, the polypeptide humoral substance produced mainly by the alpha cells of the pancreas, is generally considered as a metabolic hormone. Its influence on carbohydrate metabolism has been widely studied and is fairly well known.

In addition to the glycogenolytic action, glucagon has also been found to have an inhibitory effect on gastrointestinal motility1-3 and gastric acid secretion.4,5 By which mechanisms these actions are produced by glucagon and if they are of any physiological significance is not known.

The effect of glucagon on the cardiovascular system has been subject to much less study. In 1959, Shoemaker et al,6 using sulfobromophthalein (Bromsulphalein [BSP]) methods, studied the effect of glucagon on hepatic blood flow in dogs. They found an increase of blood flow which coincided with the serum glucose increase. In 1962, Merrill et al7 reported the effect of glucagon on the superior mesenteric vascular bed. In their

First Page Preview View Large
First page PDF preview
First page PDF preview
×